Amygdalin exerts antitumor activity in taxane-resistant prostate cancer cells

  • Despite recent advances in the treatment of metastatic prostate cancer (PCa), resistance development after taxane treatments is inevitable, necessitating effective options to combat drug resistance. Previous studies indicated antitumoral properties of the natural compound amygdalin. However, whether amygdalin acts on drug-resistant tumor cells remains questionable. An in vitro study was performed to investigate the influence of amygdalin (10 mg/mL) on the growth of a panel of therapy-naïve and docetaxel- or cabazitaxel-resistant PCa cell lines (PC3, DU145, and LNCaP cells). Tumor growth, proliferation, clonal growth, and cell cycle progression were investigated. The cell cycle regulating proteins (phospho)cdk1, (phospho)cdk2, cyclin A, cyclin B, p21, and p27 and the mammalian target of rapamycin (mTOR) pathway proteins (phospho)Akt, (phospho)Raptor, and (phospho)Rictor as well as integrin β1 and the cytoskeletal proteins vimentin, ezrin, talin, and cytokeratin 8/18 were assessed. Furthermore, chemotactic activity and adhesion to extracellular matrix components were analyzed. Amygdalin dose-dependently inhibited tumor growth and reduced tumor clones in all (parental and resistant) PCa cell lines, accompanied by a G0/G1 phase accumulation. Cell cycle regulating proteins were significantly altered by amygdalin. A moderate influence of amygdalin on tumor cell adhesion and chemotaxis was observed as well, paralleled by modifications of cytoskeletal proteins and the integrin β1 expression level. Amygdalin may, therefore, block tumor growth and disseminative characteristics of taxane-resistant PCa cells. Further studies are warranted to determine amygdalin’s value as an antitumor drug.

Download full text files

Export metadata

Author:Igor TsaurORCiDGND, Anita ThomasGND, Michelle Monecke, Marion Zugelder, Jochen RutzGND, Timothy Grein, Sebastian MaxeinerGND, Hui XieORCiDGND, Felix ChunORCiDGND, Florian RothweilerGND, Jindrich CinatlORCiDGND, Martin MichaelisORCiDGND, Axel HaferkampGND, Roman A. BlahetaORCiD
Parent Title (English):Cancers
Place of publication:Basel
Document Type:Article
Date of Publication (online):2022/06/24
Date of first Publication:2022/06/24
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2023/01/31
Tag:amygdalin; cabazitaxel; cabozantinib; complementary/alternative medicine (CAM); docetaxel; prostate cancer; resistant cell lines
Issue:13, art. 3111
Article Number:3111
Page Number:16
First Page:1
Last Page:16
This research was supported by the Brigitta & Norbert Muth Foundation.
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (German):License LogoCreative Commons - CC BY - Namensnennung 4.0 International